Jagbir Gill

Outcomes of Kidney Transplantation From Older Living Donors to Older Recipients

BACKGROUND More than half the newly wait-listed patients for kidney transplantation in 2005 were older than 50 years, and 13% were older than 65 years. As waiting times for a deceased donor kidney increase, these older candidates are disadvantaged by rapidly deteriorating health, often resulting in death or removal from the wait list before transplantation. STUDY DESIGN An observational cohort study was conducted using data from the Organ Procurement Transplant Network/United Network for Organ Sharing. SETTING & PARTICIPANTS All adult kidney-only transplantations performed in recipients 60 years and older from 1996 to 2005 were included. PREDICTOR The recipient cohort was stratified into 4 groups based on donor source: older living donor (OLD: living donor age > 55 years), younger living donor (YLD: living donor age </= 55 years), standard criteria deceased donor (SCD), and expanded criteria deceased donor (ECD). OUTCOMES & MEASUREMENTS Early posttransplantation outcomes, graft survival, patient survival, renal function 1 year posttransplantation, and relative risk of graft loss and patient death were compared. RESULTS Of 23,754 kidney transplantations performed in recipients 60 years and older, 7,006 were living donor transplantations (1,133 were > 55 years [OLD] and 5,873 were <or= 55 years [YLD]), 12,197 from SCDs, and 4,551 from ECDs. Early posttransplantation outcomes were best in YLD transplantations, followed by SCD and OLD transplantations. OLD transplantations were associated with inferior 3-year graft survival rates (85.7%), but similar 3-year patient survival rates (88.4%) compared with YLD (3-year graft survival, 83.4%; patient survival, 87.4%) and had superior graft survival compared with all deceased donor options. Compared with OLD transplantations, ECD transplantations were associated with a greater risk of graft loss (hazard ratio, 2.36; 95% confidence interval, 1.18 to 4.74). LIMITATIONS Observational retrospective studies using registry data are subject to inherent limitations, including the possibility of selection bias. CONCLUSIONS With superior graft and patient survival in recipients of transplants from OLDs compared with SCDs and ECDs, OLDs may be an important option for elderly transplantation candidates and should be considered for older patients with a willing and suitable older donor.

Patient and Graft Outcomes from Deceased Kidney Donors Age 70 Years and Older : An Analysis of the Organ Procurement Transplant Network/United Network of Organ Sharing Database

Background. The organ shortage has resulted in more use of older deceased donor kidneys. Data are limited on the impact of donor aged 70 years and older on transplant outcomes. We examined patient and graft outcomes of renal transplant from expanded criteria donors (ECDs) aged 70 years and older, using the Organ Procurement Transplant Network/United Network of Organ Sharing database. Methods. We identified 601 deceased donor transplants from donors older than 70 years from 2000 to 2005. The follow-up time was until May 2007. Allograft and patient survival were compared between recipients of transplants from older ECDs (age ≥70) and younger ECDs (age 50–69). The relative risk of graft loss and patient death were determined using multivariate models. Results. The adjusted relative risks of overall graft loss (hazards ratio [HR] 1.37; 95% confidence interval [CI] 1.19–1.58), death-censored graft loss (HR 1.32; 95% CI 1.09–1.61), and patient death (HR 1.37; 95% CI 1.15–1.64) were greater among recipients of transplants from older ECD kidneys. The relative risk of patient death was lower when older ECD kidneys were transplanted into recipients older than 60 compared with recipients aged 41 to 60. In contrast, the relative risk of death-censored graft loss was not increased when older ECD kidneys were transplanted into recipients older than 60. Conclusions. Transplants from older ECD kidneys are associated with a higher risk of graft loss and patient death. The risk was highest when older ECD kidneys were transplanted into recipients younger than 60 years.

Living Donor Kidney Versus Simultaneous Pancreas-Kidney Transplant in Type I Diabetics: An Analysis of the OPTN/UNOS Database

BACKGROUND AND OBJECTIVES Transplant options for type I diabetics with end-stage renal disease include simultaneous pancreas-kidney (SPKT), living donor kidney (LDKT), and deceased donor kidney transplant (DDKT). It is unclear whether SPKT offers a survival benefit over LDKT in the current era of transplantation. The authors compared outcomes of kidney transplant recipients with type I diabetes using data from the Organ Procurement and Transplant Network/United Network for Organ Sharing. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS Adult (age 20 to 59) type I diabetics who received a solitary first-time kidney transplant between 2000 and 2007 were studied. Outcomes included overall kidney graft and patient survival. Multivariate analysis was performed using a stepwise Cox proportional hazards model. RESULTS Kidney graft survival was better for recipients of LDKT compared with SPKT (P = 0.008), although patient survival was similar (P = 0.346). On multivariate analysis, LDKT was associated with lower adjusted risks over 72 mo follow-up of kidney graft failure (HR 0.71; 95% CI 0.61 to 0.83) and patient death (HR 0.78; 95% CI 0.65 to 0.94) versus SPKT. Compared with DDKT, SPKT had superior unadjusted kidney graft and patient survival, partly due to favorable SPKT donor and recipient factors. CONCLUSIONS Despite more transplants from older donors and among older recipients, LDKT was associated with superior outcomes compared with SPKT and was coupled with the least wait time and dialysis exposure. LDKT utilization should be considered in all type I diabetics with an available living donor, particularly given the challenges of ongoing organ shortage.

Outcomes of Dual Adult Kidney Transplants in the United States: An Analysis of the OPTN/UNOS Database

Background. The organ shortage has resulted in increased use of kidneys from expanded criteria donors (ECD). For ECD kidneys unsuitable for single use, dual kidney transplants (DKT) may be possible. There are limited data comparing outcomes of DKT to single kidney ECD transplants, making it unclear where DKT fits in the current allocation scheme. Our purpose was to compare outcomes of DKT and ECD transplants in the United States. Methods. From 2000 to 2005, a total of 625 DKT, 7686 single kidney ECD, and 6,044 SCD transplants from donors aged ≥50 years were identified from the Organ Procurement and Transplantation Network/United Network for Organ Sharing data. Allograft survival was the primary outcome. Results. DKT comprised 4% of kidney transplants from donors aged ≥50 years. Compared to the ECD donor group, the DKT donor group was older (mean age 64.6±7.7 years vs. 59.9±6.2 years) and consisted of more African Americans (13.1% vs. 9.9%), and more diabetic donors (16.3% vs. 10.4%; P<0.001). Mean cold ischemic time was longer in DKT (22.2±9.7 hr), but rates of delayed graft function were lower (29.3%) compared to ECD transplants (33.6%, P=0.03). Three-year overall graft survival was 79.8% for DKT and 78.3% for ECD transplants. Conclusion. DKT were infrequent and had outcomes comparable to ECD transplants, despite the use of organs from higher risk donors. With a more upfront approach to DKT by offering this option to patients at the time of wait-listing as part of an ECD algorithm, we may be able to further optimize outcomes of DKT and minimize discard of potential organs.

Immunosuppression of the elderly kidney transplant recipient.

The growing number of elderly patients with end-stage kidney disease awaiting transplantation has resulted in a corresponding rise in the number of elderly transplant recipients. In this paper, we review existing literature on age-related changes, transplant outcomes, and complications in the elderly in an attempt to propose a tailored approach to immunosuppression management in this group of patients. Despite the fact that the benefit of transplantation in the elderly is well established, clinical trials evaluating the safety and efficacy of immunosuppression regimens are lacking. Until such data exists, immunosuppression of the elderly transplant recipient should be based on the traditional principles which guide all transplant protocols and consideration of factors that are unique to the elderly. There are limited data regarding age-related changes in immune function and metabolism of immunosuppression agents in this population. Results of registry data analyses suggest that the risk of acute rejection decreases with age; however, the impact of acute rejection on long-term allograft function is greater in this population. There is also an increased risk of infection and adverse events posttransplantation among these patients. Elderly patients are more likely to receive organs from extended criteria donors and the impact of donor factors on transplant outcomes must therefore be considered. Taking these factors into consideration, we propose an approach to immunosuppression in the elderly based on individual risk stratification of treatment failure and the potential for adverse events.

The older living kidney donor: Part of the solution to the organ shortage.

Background. Strategies to increase kidney transplantation are urgently needed. Methods. We studied all (n=73,073) first kidney-only transplant recipients in the United States between 1995 and 2003 to determine the incidence and outcomes of living donor transplantation as a function of donor age. Because 90% of living donors were <55 years, we defined older living donors as ≥55 years. Factors associated with transplantation from older living donors and the association of living donor age with allograft function and survival were determined. Results. Recipients of older age, female gender, white race, and preemptive transplants had higher odds of older living donor transplantation. Older living donor transplantation was more likely from spousal donors rather than blood relatives, and more likely when a husband was the donor. The glomerular filtration rate (GFR) one year after transplantation decreased with increasing donor age (P<0.001). Graft survival from living donors ≥55 years was 85% and 76% at three and five years (compared to 89% and 82% with living donors <55 years, and 82% and 73% with deceased donors <55 years). In a multivariate model, the risk of graft loss with living donors 55–64 years was similar to that with deceased donors <55 years, while recipients from living donors 65–69 years (HR=1.3, 95% CI: 1.1–1.7) and >70 years (HR=1.7, 95% CI: 1.1–2.6) had a higher relative risk of graft loss. Conclusions. Outcomes are excellent with living donors <65 years. Expanded use of older living donors may help meet the demand for transplantation.

Induction Immunosuppressive Therapy in the Elderly Kidney Transplant Recipient in the United States

BACKGROUND AND OBJECTIVES The choice of induction agent in the elderly kidney transplant recipient is unclear. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS The risks of rejection at 1 year, functional graft loss, and death by induction agent (IL2 receptor antibodies [IL2RA], alemtuzumab, and rabbit antithymocyte globulin [rATG]) were compared among five groups of elderly (≥60 years) deceased-donor kidney transplant recipients on the basis of recipient risk and donor risk using United Network of Organ Sharing data from 2003 to 2008. RESULTS In high-risk recipients with high-risk donors there was a higher risk of rejection and functional graft loss with IL2RA versus rATG. Among low-risk recipients with low-risk donors there was no difference in outcomes between IL2RA and rATG. In the two groups in which donor or recipient was high risk, there was a higher risk of rejection but not functional graft loss with IL2RA. Among low-risk recipients with high-risk donors, there was a trend toward a higher risk of death with IL2RA. CONCLUSIONS rATG may be preferable in high-risk recipients with high-risk donors and possibly low-risk recipients with high-risk donors. In the remaining groups, although rATG is associated with a lower risk of acute rejection, long-term outcomes do not appear to differ. Prospective comparison of these agents in an elderly cohort is warranted to compare the efficacy and adverse consequences of these agents to refine the use of induction immunosuppressive therapy in the elderly population.

Kidney transplant outcomes in patients with Fabry disease.

Background. Fabry disease is a rare but important cause of end-stage renal disease (ESRD) among young men. Postkidney transplantation outcomes among patients with Fabry disease remain controversial. Methods. Using data from Organ Procurement Transplant Network/United Network for Organ Sharing, 197 kidney transplant recipients with ESRD because of Fabry disease from 1987 to 2007 were identified. We compared rates of graft loss and death with those of kidney transplant recipients with other (non-Fabry) causes of ESRD. Fabry patients were then compared with a 10:1 matched cohort of transplant recipients with other causes of ESRD. Results. Five-year graft survival was superior among Fabry patients (74%) compared with those with other causes of ESRD (69%), but was similar to those in the matched cohort (P=0.64). Five-year patient survival among Fabry patients (81%) was similar to those with other causes of ESRD (P=0.33), but was inferior to the matched cohort (90%). Cox multivariate analysis revealed that Fabry patients had a 40% lower risk of returning to dialysis compared with both matched and unmatched cohorts, but had a higher risk of death (2.15; 1.52–3.02) compared with the matched cohort. Conclusion. This analysis of 197 kidney transplant recipients with Fabry indicates that they have superior graft survival and similar patient survival compared with patients with other causes of ESRD. However, Fabry patients had a higher risk of death compared with a matched cohort of patients with other causes of ESRD. This requires further investigation and may suggest a need for further attention to the minimization of cardiovascular death in this group of patients.

Outcomes of Simultaneous Heart–Kidney Transplant in the US: A Retrospective Analysis Using OPTN/UNOS Data

Simultaneous heart–kidney transplantation (SHK) remains uncommon in the US. We examined outcomes of SHK compared to heart transplant alone (HTA) and deceased donor kidney transplant (DDKT).

Policy Statement of Canadian Society of Transplantation and Canadian Society of Nephrology on Organ Trafficking and Transplant Tourism

)wasdevelopedafteradirectivefromtheWorldHealthAssemblyin2004(resolution57.18),whichurgedmemberstates:“totakemeasurestoprotectthepoorestand vulnerable groups from transplant tourism and the saleof tissues and organs, including attention to the wider prob-lemofinternationaltraffickinginhumantissuesandorgans”(